STUDY OF MICROVASCULAR DAMAGE IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA
NCT07615244 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79
Last updated 2026-05-29
Summary
The goal of this interventional, non-pharmacological clinical study is to assess microcirculatory dysfunction in patients with thrombotic thrombocytopenic purpura (TTP), both during the acute phase and in remission, compared with the general population.
Microcirculatory damage will be defined as the presence of at least one abnormal instrumental finding among brain magnetic resonance imaging (MRI), optical coherence tomography angiography (OCT-A), and nailfold videocapillaroscopy.
This is a monocentric, national study including two patient cohorts:
Cohort 1: patients enrolled during the acute phase Cohort 2: patients enrolled during remission Participants will be followed for three years with a total of five study visits.
Researchers will not test any drug but will perform detailed clinical, laboratory, and instrumental assessments to evaluate microvascular involvement over time.
Participants will:
* Undergo clinical evaluation, including internal medicine and neurological assessments
* Provide blood and urine samples for laboratory analyses
* Undergo instrumental examinations such as brain MRI, OCT-A, and nailfold videocapillaroscopy
* Receive psychological/neuropsychological evaluations
* Attend follow-up visits over a 3-year period (at baseline, 3 months \[cohort 1 only\], 12, 24, and 36 months)
Conditions
- TTP - Thrombotic Thrombocytopenic Purpura
Interventions
- DIAGNOSTIC_TEST
-
Factor VIII (FVIII)
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
Von Willebrand factor (VWF) antigen
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
VWF:RCo
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
VWF-propeptide
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
VWF multimers
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
sP-selectin
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
sCD40L
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
F1+2
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
VEGF-A
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
VCAM
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
ICAM
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
IL-1β
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
IL-6
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
PTX3
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
BlyS
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
Neutrophil elastase and myeloperoxidase (NETs) markers
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
soluble C5b-9
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
C5a
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
NFL
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
GFAP
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
evaluation of thrombus formation with Total Thrombus formation Analysis System (T-TAS)
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
Microfluidic Flow Chamber
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- GENETIC
-
Whole exome sequencing - WES
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
- DIAGNOSTIC_TEST
-
Proteomic Analysis
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
Sponsors & Collaborators
-
Istituto Auxologico Italiano
collaborator OTHER -
Centro Cardiologico Monzino
collaborator OTHER -
Politecnico di Milano
collaborator OTHER -
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-28
- Primary Completion
- 2031-01-31
- Completion
- 2032-01-31
Countries
- Italy
Study Locations
More Related Trials
-
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
NCT00726544 ·Status: TERMINATED ·Phase: PHASE2
-
Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
NCT05371743 ·Status: UNKNOWN
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102323 ·Status: COMPLETED ·Phase: PHASE3
-
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
NCT00774202 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
NCT00251277 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of IVIG-L in ITP Patients
NCT00151840 ·Status: COMPLETED ·Phase: PHASE3
-
Longitudinal Observational Study on Immune Thrombocytopenia
NCT07068425 ·Status: NOT_YET_RECRUITING
-
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT02614846 ·Status: UNKNOWN ·Phase: PHASE1
-
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
NCT00161564 ·Status: WITHDRAWN ·Phase: PHASE2
-
TGD001 Treatment in Thrombotic Microangiopathies
NCT07459114 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
NCT00571467 ·Status: TERMINATED ·Phase: PHASE1
-
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
NCT07205861 ·Status: RECRUITING
-
The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)
NCT00937131 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
NCT03866577 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura
NCT07310342 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
NCT00162006 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00454857 ·Status: COMPLETED
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00102336 ·Status: COMPLETED ·Phase: PHASE3
-
Italian iTTP Registry
NCT06376786 ·Status: RECRUITING
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
NCT03102593 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
NCT02273960 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
NCT02649504 ·Status: WITHDRAWN ·Phase: PHASE3
-
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748 ·Status: RECRUITING ·Phase: PHASE1
-
Association of TNFAIP3 With Immune-mediated TTP
NCT06928233 ·Status: RECRUITING ·Phase: NA
-
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
NCT01257269 ·Status: RECRUITING